Biohaven Ltd.

Day range

$13.70 – $14.70

Open

$13.94

Prev close

$13.88

Volume

1.45M

Market cap

$2.1B

Shares out

151.04M

P/E

—

P/S

—

P/B

171.53

P/FCF

—

ROE

-4801.5%

ROA

-158.3%

Debt/Equity

21.23

Div yield

0.00%

As of Oct 23, 2026

• Business updateOct 22, 2026

  On October 22, 2026, Biohaven Ltd. (the Company) provided an update on the spinocerebeller ataxia (SCA) program.

• Licensing agreementOct 15, 2026

  On October 8, 2026, Biohaven Ltd., together with its wholly owned subsidiaries (the "Company"), entered into a Collaboration and License Agreement ... with Ono Pharmaceutical Co., Ltd. ("Ono"). Pursuant to the License Agreement, the Company granted Ono an exclusive, royalty-bearing license ... to develop and commercialize the Company's MoDE™ pan IgG degrader portfolio ... in Japan, South Korea, Taiwan and the countries of the Association of Southeast Asian Nations.

• Regulatory decisionSep 10, 2026

  FDA instructed the Company to pause new enrollment until additional clarifying nonclinical studies are completed, and issued a partial clinical hold letter on September 4, 2026 that pauses new patient enrollment pending the results of additional nonclinical data regarding the metabolite.

• Licensing agreementAug 26, 2026

  Under the License Agreement, SKBP will pay BBIL a non-creditable and non-refundable upfront fee of $400 million, consisting of $350 million payable at the Closing and $50 million payable one year after the Closing. BBIL will also be eligible to receive up to $150 million in one-time development and regulatory milestone payments. In addition, SKBP will pay BBIL tiered royalties ranging from the mid-teens to the low twenties on U.S. net sales of opakalim and certain other antiseizure products.

• Director appointmentAug 7, 2026

  On August 3, 2026, the Board of Directors (the "Board") of Biohaven Ltd. (the "Company") appointed John Yetimoglu as a director, effective August 6, 2026. Mr. Yetimoglu will serve in the class of directors whose term will expire at the Company's 2027 Annual Meeting of Shareholders. Mr. Yetimoglu has also been appointed as a member of the Nominating and Governance Committee of the Board.

Days to cover

6.4

Short interest

19.05M

Avg volume

2.96M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Bexorg Awarded Up to $28.3 Million from ARPA-H to Advance Human Brain Translational Pharmacology for CNS Drug Development
  positiveGlobeNewswire Inc.· Oct 7, 2026
• Why Biohaven Stock Was Rocking the Market This Week
  positiveThe Motley Fool· Aug 28, 2026
• Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential
  neutralThe Motley Fool· Mar 23, 2026
• Biohaven (BHVN) Stock Is Trending Overnight — Here's What You Should Know
  neutralBenzinga· Jan 14, 2026
• Stock Market Today: Dow Jones, S&P 500, Nasdaq Futures Decline After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus (UPDATED)
  positiveBenzinga· Dec 26, 2025